Who Owns Celebrex?

• Parent Company: Pfizer
• Ownership Type: Brand division
• Company Type: Publicly Traded
• Stock Ticker: NYSE: PFE

• Founded: 1998
• Founders: Pfizer (internal development)

• Founded: 1849
• Headquarters: New York, New York, USA
• Company Type: Publicly Traded
• Stock: NYSE: PFE
• Revenue: approximately $63.6 billion (FY2025)
• Employees: Approximately 88,000

Visit Pfizer website

• Headquarters: New York, New York, USA
• Manufacturing / Operations: United States, Belgium, Ireland, United Kingdom

Celebrex operates under Pfizer's comprehensive Environmental, Social and Governance (ESG) framework, which integrates sustainability practices into pharmaceutical development, manufacturing, and distribution operations. Pfizer has established ambitious environmental targets and ethical practices that support its mission of delivering innovative medicines while protecting people and the planet.

Environmental Sustainability: Pfizer has committed to achieving net-zero greenhouse gas emissions across its operations by 2040 and has implemented comprehensive climate action plans. The company exceeded its third generation GHG goal of a 20% reduction from its 2012 baseline, achieving a 33% reduction in emissions. Pfizer became the first company in the pharmaceutical sector to have its climate target validated by the Science Based Target Initiative, demonstrating leadership in environmental performance.

Climate Action: Pfizer has implemented significant renewable energy initiatives across its manufacturing facilities worldwide. The company's environmental strategy includes energy efficiency measures, water conservation programs, and waste reduction initiatives. Pfizer reports that its environmental initiatives are designed to support both regulatory compliance and long-term sustainability goals while maintaining reliable pharmaceutical production and distribution.

Responsible Manufacturing: Pfizer maintains strict environmental standards for all pharmaceutical manufacturing processes, including Celebrex production facilities. The company's manufacturing operations implement green chemistry principles, waste minimization programs, and energy-efficient production methods. Pfizer prioritizes sustainable manufacturing practices that reduce environmental impact while maintaining product quality and safety.

Patient Safety Ethics: As a prescription medication manufacturer, Pfizer maintains strong ethical standards in patient care, including comprehensive clinical trial protocols, medication safety monitoring, and transparent reporting of adverse events. The company implements rigorous quality assurance programs and follows regulatory requirements for pharmaceutical development and distribution. Pfizer's ethical framework emphasizes patient safety, medication access, and responsible healthcare practices.

Clinical Research Ethics: Pfizer conducts clinical trials for medications like Celebrex under strict ethical guidelines and regulatory oversight. The company's clinical research programs prioritize patient safety, informed consent, and transparent reporting of trial results. Pfizer's research ethics include comprehensive data integrity measures and adherence to international clinical trial standards.

Community Engagement: Pfizer supports community health initiatives through patient assistance programs, healthcare provider education, and access programs for essential medications. The company's community engagement focuses on improving access to medicines and supporting healthcare providers in underserved communities. Pfizer employees participate in volunteer programs and community service initiatives that align with the company's mission of improving global health.

Supply Chain Responsibility: Pfizer operates a comprehensive global supply chain for pharmaceutical products, with robust quality control and safety monitoring systems. The company implements temperature-controlled logistics, secure storage, and proper handling procedures for medications. Pfizer's supply chain includes sustainability initiatives such as optimized routing, reduced packaging, and efficient inventory management to minimize environmental impact while maintaining product integrity.

Ethical Business Practices: Pfizer maintains comprehensive compliance programs and ethical business conduct guidelines across all operations. The company's ethical framework includes strict adherence to healthcare regulations, anti-corruption measures, and transparent pricing practices. Pfizer's pharmaceutical operations are designed to support healthcare providers and patients with integrity and professionalism.

Celebrex has received recognition both as an innovative pharmaceutical product and through Pfizer's broader corporate achievements in sustainability and ethical business practices. The medication's development and market success have been acknowledged by healthcare organizations and industry publications.

Pharmaceutical Innovation: Celebrex was recognized as a significant advancement in COX-2 inhibitor technology when it was approved by the FDA in 1998. The medication received attention for its potential to provide pain relief with reduced gastrointestinal side effects compared to traditional NSAIDs. Celebrex's mechanism of action was acknowledged by medical professionals as an important development in arthritis and pain management.

Clinical Research Recognition: Pfizer's clinical research programs for Celebrex have received recognition for comprehensive safety monitoring and long-term outcome studies. The medication has been studied extensively in various clinical settings, and the research has been acknowledged for contributing to the understanding of COX-2 inhibitors and their role in pain management.

Pfizer's ESG Leadership: Pfizer's comprehensive ESG initiatives have received significant recognition, including validation of its climate targets by the Science Based Target Initiative. The company's 33% reduction in greenhouse gas emissions has been acknowledged as a significant achievement in the pharmaceutical sector. Pfizer's sustainability leadership has been recognized by industry organizations for demonstrating that large pharmaceutical companies can achieve meaningful environmental improvements.

Corporate Responsibility Recognition: Pfizer has received recognition for its corporate responsibility programs, including patient assistance programs and community health initiatives. The company's commitment to improving access to medicines and supporting healthcare providers has been acknowledged by healthcare organizations and industry associations.

Healthcare Industry Leadership: Pfizer's position as one of the world's largest pharmaceutical companies has been recognized by industry publications for innovation in drug development and global healthcare leadership. The company's comprehensive approach to pharmaceutical research and development has been acknowledged for advancing medical science and improving patient outcomes worldwide.

Celebrex has faced significant regulatory scrutiny and controversies related to cardiovascular safety concerns, which led to major changes in the COX-2 inhibitor market. These events have shaped the medication's current usage and regulatory status.

Cardiovascular Safety Concerns: In 2004-2005, major concerns emerged about the cardiovascular safety of COX-2 inhibitors, including Celebrex. The FDA conducted extensive safety reviews after Vioxx (another COX-2 inhibitor) was withdrawn from the market due to increased cardiovascular risk. Celebrex was found to have a lower but still present cardiovascular risk profile compared to traditional NSAIDs.

FDA Regulatory Actions: The FDA implemented significant regulatory actions affecting Celebrex in 2005, including requiring a black box warning about cardiovascular and gastrointestinal risks. The FDA also required Pfizer to conduct long-term safety studies to better understand Celebrex's cardiovascular profile. These regulatory actions significantly impacted Celebrex's market position and prescribing patterns.

Prescription Decline: Following the safety concerns and regulatory actions, Celebrex prescriptions declined significantly from their peak levels. Many healthcare providers reduced or eliminated Celebrex prescriptions in favor of traditional NSAIDs or alternative pain management approaches. The medication's market share in the arthritis and pain management categories decreased substantially.

Litigation and Legal Challenges: Pfizer faced numerous lawsuits related to Celebrex's cardiovascular safety, including claims that the company failed to adequately warn patients and healthcare providers about potential risks. The company resolved many of these lawsuits through settlements, though the exact financial details were not publicly disclosed.

Current Safety Profile: Celebrex remains on the market with a more restricted usage pattern and comprehensive safety monitoring. The medication is now prescribed with greater caution, particularly for patients with existing cardiovascular risk factors. Pfizer has implemented enhanced safety monitoring and educational programs for healthcare providers prescribing Celebrex.

Ongoing Research: Pfizer continues to conduct long-term safety studies on Celebrex to better understand its cardiovascular risk profile and appropriate patient populations. The company's research has helped refine understanding of COX-2 inhibitors and their role in pain management, contributing to more informed prescribing practices.